SOLAL UBIQUINOL NOW IN STOCK
Has Your Co-enzyme Q10 Become Obsolete?
There
are 2 forms of Co enzyme Q10: Ubiquinol and Ubiquinone. All co-enzyme Q10
products on the South African market, except for Solal’s Ubiquinol, contain
the less absorbable, less effective and less protective ubiquinone form.
Ubiquinol
co-enzyme Q10 is more effective than the ordinary ubiquinone form of
co-enzyme Q10 because:
ü it is already in the
body’s ‘ready-to-use’ form. The ubiquinone form must first to be converted into the
active ubiquinol form before the body can use it. This conversion
process is slow, and slows down even more with aging. This makes it especially
important to use the ubiquinol form as one gets older.
ü it is absorbed up to
8X better7-11. Poor absorption of
ubiquinone co-enzyme Q10 has historically been one of main barriers to
obtaining the high blood levels required to slow aging and protect the
heart.
ü it is 40% better at
slowing down the aging process than ordinary ubiquinone co-enzyme Q1034.
ü it maintains CoQ10
blood levels 66% better12. These sustained levels are essential
for heart protection.
ü it ensures the
correct ratio of ubiquinol:ubiquinone in the blood (above 90%)1.
ü it enters cells
more easily and it therefore more able to keep cells alive by supplying
energy to the mitochondria within the cell48.
ü it reduces
fatigue 90% more effectively.38
Solal is the only brand of Ubiquinol in SouthAfrica
Solal’sUbiquinol is stabilised to prevent oxidation back
intoless effective ordinary co-enzyme Q10(ubiquinone).
Why
is Ubiquinol so important?
Ubiquinol
ensures the cells have the energy that they need to stay alive
and function properly. When the levels of ubiquinol in your bloodstream are
low, your cells and organs (especially the ones that need a lot of energy
such as your heart and brain) struggle to keep up with energy
demands. This causes cell starvation and oxidative damage. Cellular
energy production can be maintained at youthful levels, by supplementing
with SOLAL’s Ubiquinol. This helps prevent many of the harmful effects
of aging, and offers particular protection to the heart and brain.
Ubiquinol
is the reduced form of ubiquinone which means that, unlike ordinary ubiquinone co-q 10, it more
effectively donates electrons to neutralise free radicals that
damage the cells’ energy producing mitochondria4.
Ubiquinol
helps prevent many age related disorders1,37
such as heart disease, brain/neurological disorders, cancers, kidney
disease, liver disease, pancreas disorders, adrenal imbalances and
diabetes.
What
causes low levels of CoQ10?
Co-enzyme
Q10 synthesis decreases as one ages and has been positively correlated with
increased risk of various degenerative diseases13-33.
There
are 3 main causes of drastic drops in blood-ubiquinol levels:
Age43-45, Diseased states
(e.g. diabetes, heart disease) and Cholesterol medicines (known as
“statins”)39-42. The irony is that at the time that you need to protect your
heart the most (when you are getting older, have a disease such as
diabetes, or are taking cholesterol lowering medicine), you have the least
available heart-protecting ubiquinol in the blood.
In fact,
taking statin cholesterol medications, without supplementing with
ubiquinol, can cause severe heart damage49-51.
If you areaging, suffer from any disease, or are taking
statincholesterol medicines, it is imperative that yousupplement with
Ubiquinol-Coenzyme Q10
References:
1.
Faloon, W. Report: Has your CoQ0
become obsolete? LE Magazine. January 2007.
2.
Ren Z, Ding W, Su Z, et al. Mechanisms
of brain injury with deep hypothermic circulatory arrest and protective
effects of coenzyme Q10. J Thorac Cardiovasc Surg. 1994 Jul;108(1):126-33.
3.
Available at: http://www.patentstorm.us/patents/6184255-fulltext.html.
Accessed October 23, 2006.
4.
Weber C, Jakobsen TS, Mortensen SA,
Paulsen G, Holmer G. Effect of dietary coenzyme Q10 as an antioxidant in
human plasma. Mol Aspects Med. 1994;15 Suppls97-102.
5.
Unpublished data, Kaneka Corp.
6.
Kazunori H, Mitsuaki K, Hideyuki, K
Hiroshi, K Kenji, F Mikio, K. Study on safety and bioavailability of
ubiquinol (Kaneka QHtm). Regul Toxicol Pharmacol. 2006 Aug 17.
7.
46. Hosoe K, Kitano M, Kishida H, et
al. Study on safety and bioavailability of ubiquinol (Kaneka QH(trade
mark)) after single and 4-week multiple oral administration to healthy
volunteers. Regul Toxicol Pharmacol. 2006 Aug 17.
8.
Shults CW, Oakes D, Kieburtz K, et al.
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of
the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.
9.
Shults CW, Flint BM, Song D, Fontaine
D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s
disease. Exp Neurol. 2004 Aug;188(2):491-4.
10. Kurowska EM, Dresser G, Deutsch L,
Bassoo E, Freeman DJ. Relative bioavailability and antioxidant potential of
two coenzyme q10 preparations. Ann Nutr Metab. 2003;47(1):16-21.
11. Shults CW, Haas RH, Beal MF. A
possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s
disease. Biofactors. 1999;9(2-4):267-72.
12. CoQ10 reducing activity in rats.
Unpublished data, Kaneka Corp.
13. Available at: http://cancerweb.ncl.ac.uk/cancernet/600916.html.
Accessed October 19, 2006.
14. Ernster L, Forsmark-Andree P.
Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig.
1993;71(8 Suppl):S60-5.
15. Passi S, De PO, Puddu P, Littarru GP.
Lipophilic antioxidants in human sebum and aging. Free Radic Res. 2002
Apr;36(4):471-7.
16. Naini A, Lewis VJ, Hirano M, DiMauro
S. Primary coenzyme Q10 deficiency and the brain. Biofactors.
2003;18(1-4):145-52.
17. Siemieniuk E and Skrzydlewska E.
Coenzyme Q10: its biosynthesis and biological significance in animal
organisms and in humans. Postepy Hig Med Dosw (Online). 2005;59:150-9.
18. Rusciani L, Proietti I, Rusciani A, et
al. Low plasma coenzyme Q10 levels as an independent prognostic factor for
melanoma progression. J Am Acad Dermatol. 2006 Feb;54(2):234-41.
19. Kontush A, Schippling S, Spranger T,
Beisiegel U. Plasma ubiquinol-10 as a marker for disease: is the assay
worthwhile? Biofactors. 1999;9(2-4):225-9.
20. Yamamoto Y, Yamashita S. Plasma
ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and
hepatoma, and in patients treated with percutaneous transluminal coronary
reperfusion. Biofactors. 1999;9(2-4):241-6.
21. Sohmiya M, Tanaka M, Suzuki Y, et al.
An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS
patients. J Neurol Sci. 2005 Jan 15;228(1):49-53.
22. Folkers K, Osterborg A, Nylander M,
Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a
serious deficiency in patients with cancer. Biochem Biophys Res Commun.
1997 May 19;234(2):296-9.
23. Portakal O, Ozkaya O, Erden IM, et al.
Coenzyme Q10 concentrations and antioxidant status in tissues of breast
cancer patients. Clin Biochem. 2000 Jun;33(4):279-84.
24. Lockwood K, Moesgaard S, Yamamoto T,
Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the
regression of metastases. Biochem Biophys Res Commun. 1995 Jul
6;212(1):172-7.
25. Lockwood K, Moesgaard S, Folkers K.
Partial and complete regression of breast cancer in patients in relation to
dosage of coenzyme Q10. Biochem Biophys Res Commun. 1994 Mar
30;199(3):1504-8.
26. Palan PR, Mikhail MS, Shaban DW,
Romney SL. Plasma concentrations of coenzyme Q10 and tocopherols in
cervical intraepithelial neoplasia and cervical cancer. Eur J Cancer Prev.
2003 Aug;12(4):321-6.
27. Jolliet P, Simon N, Barre J, et al.
Plasma coenzyme Q10 concentrations in breast cancer: prognosis and
therapeutic consequences. Int J Clin Pharmacol Ther. 1998 Sep;36(9):506-9.
28. Muller T, Buttner T, Gholipour AF,
Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in
patients with Parkinson’s disease. Neurosci Lett. 2003 May 8;341(3):201-4.
29. Ferrante KL, Shefner J, Zhang H, et
al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology.
2005 Dec 13;65(11):1834-6.
30. Mariani C, Bresolin N, Farina E, et
al. Muscle biopsy in Alzheimer’s disease: morphological and biochemical
findings. Clin Neuropathol. 1991 Jul;10(4):171-6.
31. Koroshetz WJ, Jenkins BG, Rosen BR,
Beal MF. Energy metabolism defects in Huntington’s disease and effects of
coenzyme Q10. Ann Neurol. 1997 Feb;41(2):160-5.
32. Siciliano G, Mancuso M, Tedeschi D, et
al. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in
myotonic dystrophy. Brain Res Bull. 2001 Oct 1;56(3-4):405-10.
33. Folkers K, Simonsen R. Two successful
double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies
and neurogenic atrophies. Biochim Biophys Acta. 1995 May 24;1271(1):281-6.
34. Yan J, Fujii K, Yao J, et al. Reduced
coenzyme Q10 supplementation decelerates senescence in SAMP1 mice. Exp
Gerontol. 2006 Feb;41(2):130-40.
35. Bowry VW, Mohr D, Cleary J, Stocker R.
Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human
low density lipoprotein. J Biol Chem. 1995 Mar 17;270(11):5756-63.
36. Ingold KU, Bowry VW, Stocker R,
Walling C. Autoxidation of lipids and antioxidation by alpha-tocopherol and
ubiquinol in homogeneous solution and in aqueous dispersions of lipids:
unrecognized consequences of lipid particle size as exemplified by
oxidation of human low density lipoprotein. Proc Natl Acad Sci U S A. 1993
Jan 1;90(1):45-9.
37. Report:
Advanced absorbtion of ubiquinol CoQ10. LE Magazine.
38. KANEKA CORP. Anti-fatigue effect in
rats. Unpublished data, Kaneka Corp.
39. Bargossi AM, Grossi G, et al.
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction
induced by the HMG CoA reductase inhibitors. Mol Aspect Med.
1994;15(S):187-193.
40. Langsjoen PH, Langsjoen AM. The
clinical use of HMG CoA-reductase inhibitors and the associated depletion
of coenzyme Q10. A review of animal and human publications. Biofactors.
2003;18(1-4):101-11.
41. Mabuchi H, Higashikata T, Kawashiri M,
Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction
of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in
hypercholesterolemic patients. Journal of Atheroscler Thromb.
2005;12(2):111-9.
42. Mortensen SA, Leth A. et al.
Dose-related decrease of serum CoQ10 during treatment with HMG-CoA
reductase inhibitors. Mol Aspect Med. 1997; 1&(S):137-144.
43. Hoppe U, Bergemann J, et al. Coenzyme
Q10, a cutaneous antioxidant and energizer. Biofactors. 1999;9(2-4):371-8.
44. Kalen A, Appelkvist EL, Dallner G.
Age-related changes in the lipid compositions of rat and human tissues.
Lipids. 1989 Jul;24(7):579-84.
45. Rosenfeldt FL, Pepe S, et al. Coenzyme
Q10 improves the tolerance of the senescent myocardium to aerobic and
ischemic stress: studies in rats and in human trial tissue. Biofactors.
1999;9(2-4):291-9.
46. Matthews RT, Yang L, Browne S, Baik M,
Beal MF. Coenzyme Q10 administration increases brain mitochondrial
concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA.
1998 Jul 21;95(15):8892-7.
47. Menke T, Gille G, Reber F, et al.
Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by
preserving the mitochondrial membrane potential. Biofactors.
2003;18(1-4):65-72.
48. James AM, Cocheme HM, Smith RA, Murphy
MP. Interactions of mitochondria-targeted and untargeted ubiquinones with
the mitochondrial respiratory chain and reactive oxygen species.
Implications for the use of exogenous ubiquinones as therapies and
experimental tools. J Biol Chem. 2005 Jun 3;280(22):21295-312.
49.
Silver MA, Langsjoen PH, Szabo S,
Patil H, Zelinger A; Effect of atorvastatin on left ventricular diastolic
function and ability of coenzyme Q10 to reverse that dysfunction. Am J
Cardiol. 2004 Nov 15;94(10):1306-10
50.
Nawarskas, James J. PharmD; HMG-CoA
Reductase Inhibitors and Coenzyme Q10; Cardiology in Review. 13(2):76-79,
March/April 2005.
51.
Levy HB, Kohlhaas HK; Considerations
for supplementing with coenzyme Q10 during statin therapy; Ann
Pharmacother. 2006 Feb;40(2):290-4. Epub 2006 Jan 31.
